Kasey Rivas

1.6k total citations
19 papers, 838 citations indexed

About

Kasey Rivas is a scholar working on Infectious Diseases, Public Health, Environmental and Occupational Health and Parasitology. According to data from OpenAlex, Kasey Rivas has authored 19 papers receiving a total of 838 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 9 papers in Public Health, Environmental and Occupational Health and 7 papers in Parasitology. Recurrent topics in Kasey Rivas's work include HIV/AIDS drug development and treatment (8 papers), Malaria Research and Control (8 papers) and Computational Drug Discovery Methods (6 papers). Kasey Rivas is often cited by papers focused on HIV/AIDS drug development and treatment (8 papers), Malaria Research and Control (8 papers) and Computational Drug Discovery Methods (6 papers). Kasey Rivas collaborates with scholars based in United States, Thailand and Germany. Kasey Rivas's co-authors include Wesley C. Van Voorhis, Michael H. Gelb, Debopam Chakrabarti, Kohei Yokoyama, Frederick S. Buckner, Andrew D. Hamilton, Ekachai Jenwitheesuk, J. Horst, Ram Samudrala and Tara Kerin and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Medicinal Chemistry and The Journal of Infectious Diseases.

In The Last Decade

Kasey Rivas

19 papers receiving 822 citations

Peers

Kasey Rivas
Iain D. Kerr United States
Paula M. Dulski United States
T.L. Arakaki United States
Irene Chau Canada
Manoj Munde United States
Jill M. Combrinck South Africa
Janette Reader South Africa
Iain D. Kerr United States
Kasey Rivas
Citations per year, relative to Kasey Rivas Kasey Rivas (= 1×) peers Iain D. Kerr

Countries citing papers authored by Kasey Rivas

Since Specialization
Citations

This map shows the geographic impact of Kasey Rivas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kasey Rivas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kasey Rivas more than expected).

Fields of papers citing papers by Kasey Rivas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kasey Rivas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kasey Rivas. The network helps show where Kasey Rivas may publish in the future.

Co-authorship network of co-authors of Kasey Rivas

This figure shows the co-authorship network connecting the top 25 collaborators of Kasey Rivas. A scholar is included among the top collaborators of Kasey Rivas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kasey Rivas. Kasey Rivas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Huang, Wenlin, Matthew A. Hulverson, Ryan Choi, et al.. (2019). Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. Journal of Medicinal Chemistry. 62(6). 3135–3146. 23 indexed citations
2.
Hulverson, Matthew A., Igor Bruzual, Wenlin Huang, et al.. (2018). Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis. The Journal of Infectious Diseases. 219(9). 1464–1473. 11 indexed citations
3.
Hulverson, Matthew A., Sumiti Vinayak, Ryan Choi, et al.. (2017). Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. The Journal of Infectious Diseases. 215(8). 1275–1284. 43 indexed citations
4.
Ojo, Kayode K., Sriveny Dangoudoubiyam, Shiv K. Verma, et al.. (2016). Selective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy. International Journal for Parasitology. 46(13-14). 871–880. 23 indexed citations
5.
Schaefer, Deborah A., Jennifer A. Zambriski, Kayode K. Ojo, et al.. (2016). Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis. The Journal of Infectious Diseases. 214(12). 1856–1864. 49 indexed citations
6.
Castellanos-González, Alejandro, Wenlin Huang, Zhongsheng Zhang, et al.. (2016). A Novel Calcium-Dependent Kinase Inhibitor, Bumped Kinase Inhibitor 1517, Cures Cryptosporidiosis in Immunosuppressed Mice. The Journal of Infectious Diseases. 214(12). 1850–1855. 25 indexed citations
7.
Castellanos-González, Alejandro, A. Clinton White, Kayode K. Ojo, et al.. (2013). A Novel Calcium-Dependent Protein Kinase Inhibitor as a Lead Compound for Treating Cryptosporidiosis. The Journal of Infectious Diseases. 208(8). 1342–1348. 63 indexed citations
8.
Kerin, Tara, Anita Ramanathan, Kasey Rivas, et al.. (2012). A Noncoding RNA Antisense to Moesin at 5p14.1 in Autism. Science Translational Medicine. 4(128). 128ra40–128ra40. 102 indexed citations
9.
Hast, Michael A., Steven Fletcher, Michelle A. Blaskovich, et al.. (2009). Structural Basis for Binding and Selectivity of Antimalarial and Anticancer Ethylenediamine Inhibitors to Protein Farnesyltransferase. Chemistry & Biology. 16(2). 181–192. 29 indexed citations
10.
Jenwitheesuk, Ekachai, et al.. (2008). Novel paradigms for drug discovery: computational multitarget screening. Trends in Pharmacological Sciences. 29(2). 62–71. 89 indexed citations
11.
Fletcher, Steven, Kasey Rivas, William P. Katt, et al.. (2008). Potent, Plasmodium-Selective Farnesyltransferase Inhibitors That Arrest the Growth of Malaria Parasites: Structure−Activity Relationships of Ethylenediamine-Analogue Scaffolds and Homology Model Validation. Journal of Medicinal Chemistry. 51(17). 5176–5197. 25 indexed citations
12.
Bulbule, Vivek J., Kasey Rivas, Christophe L. M. J. Verlinde, Wesley C. Van Voorhis, & Michael H. Gelb. (2008). 2-Oxotetrahydroquinoline-Based Antimalarials with High Potency and Metabolic Stability. Journal of Medicinal Chemistry. 51(3). 384–387. 20 indexed citations
13.
Srinivas, O., Kasey Rivas, Kohei Yokoyama, et al.. (2007). 2-Oxo-tetrahydro-1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials. Bioorganic & Medicinal Chemistry Letters. 18(2). 494–497. 53 indexed citations
14.
Voorhis, Wesley C. Van, Kasey Rivas, Laxman Nallan, et al.. (2007). Efficacy, Pharmacokinetics, and Metabolism of Tetrahydroquinoline Inhibitors of Plasmodium falciparum Protein Farnesyltransferase. Antimicrobial Agents and Chemotherapy. 51(10). 3659–3671. 26 indexed citations
15.
Srinivas, O., Vivek J. Bulbule, Kasey Rivas, et al.. (2007). Second Generation Tetrahydroquinoline-Based Protein Farnesyltransferase Inhibitors as Antimalarials. Journal of Medicinal Chemistry. 50(19). 4585–4605. 53 indexed citations
16.
Glenn, Matthew P., Kasey Rivas, Kohei Yokoyama, et al.. (2006). Structurally Simple, Potent, Plasmodium Selective Farnesyltransferase Inhibitors That Arrest the Growth of Malaria Parasites. Journal of Medicinal Chemistry. 49(19). 5710–5727. 26 indexed citations
17.
Glenn, Matthew P., Oliver Hucke, Christophe L. M. J. Verlinde, et al.. (2005). Structurally Simple Farnesyltransferase Inhibitors Arrest the Growth of Malaria Parasites. Angewandte Chemie International Edition. 44(31). 4903–4906. 29 indexed citations
18.
Nallan, Laxman, Kasey Rivas, Kohei Yokoyama, et al.. (2005). Protein Farnesyltransferase Inhibitors Exhibit Potent Antimalarial Activity. Journal of Medicinal Chemistry. 48(11). 3704–3713. 147 indexed citations
19.
Glenn, Matthew P., Oliver Hucke, Christophe L. M. J. Verlinde, et al.. (2005). Structurally Simple Farnesyltransferase Inhibitors Arrest the Growth of Malaria Parasites. Angewandte Chemie. 117(31). 4981–4984. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026